A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
Public ClinicalTrials.gov record NCT03150862. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
Study identification
- NCT ID
- NCT03150862
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- BeiGene USA, Inc.
- Industry
- Enrollment
- 116 participants
Conditions and interventions
Conditions
Interventions
- Pamiparib Drug
- Radiation Radiation
- TMZ Drug
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 23, 2017
- Primary completion
- Mar 16, 2021
- Completion
- Mar 16, 2021
- Last update posted
- Feb 3, 2025
2017 – 2021
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Center For Neurosciences | Tucson | Arizona | 85718 | — |
| UCLA | Los Angeles | California | 90095 | — |
| University of California At San Francisco | San Francisco | California | 94143 | — |
| Sarah Cannon Research Institute (Scri) At Health One | Denver | Colorado | 80219 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Midamerica Division, Inc | Kansas City | Missouri | 64132 | — |
| Washington University in St Louis | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center Mskcc | New York | New York | 10065 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Sarah Cannon Research Institute (Scri) Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Penn State Milton S Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Thomas Jefferson University Hospital Jefferson Health | Philadelphia | Pennsylvania | 19107 | — |
| Tennessee Oncology, Pllc Nashville | Nashville | Tennessee | 37203 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| University of Virginia | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03150862, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 3, 2025 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03150862 live on ClinicalTrials.gov.